Ovarian Cancer Research Review, Issue 12

In this issue:

ASCO guideline for PARP inhibitors in the management of OC
Efficacy of maintenance olaparib for newly diagnosed advanced OC with a BRCA mutation
Binimetinib vs physician’s choice chemotherapy in recurrent or persistent LGSC
Nomogram to determine long term survival outcomes of stage I mucinous OC
Safety of surveillance in stage IA-C G1-3 ITs
Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for OC
Efficacy and toxicity of extended duration PLD in women with recurrent EOC
Nivolumab vs nivolumab and ipilimumab for recurrent or persistent OC
Olaparib and durvalumab for recurrent OC

Please login below to download this issue (PDF)